Neurizon Receives Positive EMA Opinion for NUZ-001 Orphan Designation
Tuesday, November 12, 2024
Neurizon Therapeutics has received a positive opinion from the European Medicines Agency (EMA) for Orphan Medicinal Product Designation (OMPD) for its lead drug candidate, NUZ-001, targeting Amyotrophic Lateral Sclerosis (ALS).
The OMPD designation would provide Neurizon with several benefits for NUZ-001, such as reduced regulatory fees, free protocol assistance, and a 10-year period of market exclusivity within the European Union (EU).
A formal decision from the European Commission on the orphan designation is expected in December.
This exclusivity period means that the EMA and EU Member States will not approve any other marketing authorisation applications for similar medicinal products for ALS during this time.
Neurizon is currently advancing NUZ-001 through a Phase 2/3 clinical study under the HEALEY ALS Platform Trial, with patient enrolment set to begin in the first half of 2025. The study protocol has been structured to support potential early regulatory approval.
The EMA’s positive opinion on OMPD further strengthens NUZ-001’s pathway and its potential to address urgent unmet needs in ALS.
With OMPD in the EU and Orphan Drug Designation already secured from the United States Food and Drug Administration, Neurizon is well-positioned to gain market exclusivity for NUZ-001 in key global markets for ALS treatment.
This regulatory progress highlights the potential impact of NUZ-001 for ALS patients and reinforces its commercial value as a promising therapeutic candidate.
Neurizon anticipates continued engagement with the EMA and other regulatory bodies as it advances its work to bring new treatment options to those affected by this severe condition.
Source: prnewswire.com
